drugset / Trial / NCT03473457
CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Terminated
2 enrolled
Zhujiang Hospital
Nanfang Hospital, Southern Medical University · collabSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabThe Third Affiliated Hospital of Southern Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
Acute myeloid leukemia (AML) is a group of genetically highly heterogeneous malignant disease . The disease is the most common type of adult acute leukemia. Overall survival (OS) was less than 50% in 5 years. Chimeric Antigen Receptor-transduced T cell (CAR-T) therapy is one of revolutionary targeted immunotherapy. The efficacy of CAR-T cells for the treatment of acute B lymphocytic leukemia has been widely recognized, although it start late, several clinical trials have been register in ClinicalTrials.gov.
Timeline
- Start
- 2018-04-01
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD117-CART | Unknown | 1e+06 cells/kg | — |
| Subject | CD117-CART | Unknown | 1e+07 cells/kg | — |
| Subject | CD133-CART | Unknown | 1e+06 cells/kg | — |
| Subject | CD133-CART | Unknown | 1e+07 cells/kg | — |
| Subject | CD33CART | Cell therapy | 1e+06 cells/kg | — |
| Subject | CD33CART | Cell therapy | 1e+07 cells/kg | — |
| Subject | CD34-CART | Unknown | 1e+06 cells/kg | — |
| Subject | CD34-CART | Unknown | 1e+07 cells/kg | — |
| Subject | CD38-CART | Cell therapy | 1e+06 cells/kg | — |
| Subject | CD38-CART | Cell therapy | 1e+07 cells/kg | — |
| Subject | CD56-CART | Cell therapy | 1e+06 cells/kg | — |
| Subject | CD56-CART | Cell therapy | 1e+07 cells/kg | — |
| Subject | Mucl-CART | Unknown | 1e+06 cells/kg | — |
| Subject | Mucl-CART | Unknown | 1e+07 cells/kg | — |
| Subject | Relmapirazin | Diagnostic / imaging agent | 1e+06 cells/kg | — |
| Subject | Relmapirazin | Diagnostic / imaging agent | 1e+07 cells/kg | — |